LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

35.12 -4.2

Buy Sell

Overview

Share price change

24h

Current

Min

33.6

Max

35.68

Key metrics
By Trading Economics
Income	11M 51M
Sales	39M 239M
P/E Sector Avg	11.36 110.024
EPS	1.08
Profit margin	21.242
Employees	268
EBITDA	14M 73M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+31.21% upside

Dividends
By Dow Jones
Next Earnings	24 lut 2026

Market Stats
By TradingEconomics
Market Cap	387M 2.1B
Previous open	39.32
Previous close	35.12

News Sentiment

By Acuity

50%

165 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lut 2026, 23:44 UTC

Hot Stocks

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 lut 2026, 23:20 UTC

Earnings

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 lut 2026, 22:57 UTC

Earnings

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 lut 2026, 21:59 UTC

Earnings

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 lut 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 lut 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

17 lut 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lut 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 lut 2026, 23:19 UTC

Earnings

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 lut 2026, 23:15 UTC

Earnings

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 lut 2026, 22:58 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 lut 2026, 22:58 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 lut 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 lut 2026, 22:50 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 lut 2026, 22:44 UTC

Earnings

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 lut 2026, 22:42 UTC

Earnings

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 lut 2026, 22:36 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 lut 2026, 22:36 UTC

Earnings

Santos Final Dividend 10.3 U.S. Cents/Security

17 lut 2026, 22:36 UTC

Earnings

Santos FY Underlying Profit US$898 Million, Down 25%

17 lut 2026, 22:35 UTC

Earnings

Santos FY Revenue US$4.94 Billion, Down 8%

17 lut 2026, 22:35 UTC

Earnings

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 lut 2026, 22:35 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 lut 2026, 22:34 UTC

Earnings

Santos FY Net Profit US$818 Billion, Down 33%

17 lut 2026, 22:02 UTC

Acquisitions, Mergers, Takeovers

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 lut 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 lut 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 lut 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 lut 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

31.21% upside

12 Months Forecast

Average 47.25 USD 31.21%

High 55 USD

Low 42 USD

Based on 5 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

165 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.